Noninvasive detection of inflammation-associated colon cancer in a mouse model

Neoplasia

Volumn 12, Issue 12, 2010, Pages 1054-1065

  Ericsson, Aaron C ^a   Myles, Matthew ^a   Davis, Wade ^a   Ma, Lixin ^b,c   Lewis, Michael ^c   Maggio Price, Lillian ^d   Franklin, Craig ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SMAD3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATION; CANCER GROWTH; CANCER INCIDENCE; COLITIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME REGULATION; FEMALE; HELICOBACTER BILIS; IMAGE ANALYSIS; MALE; MOUSE; MUCINOUS CARCINOMA; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

EID: 78649870102     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10940     Document Type: Article

References (72)

1. Walsh JM and Terdiman JP (2003). Colorectal cancer screening: scientific review. JAMA 289, 1288-1296.
2. Itzkowitz SH (2006). Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35, 553-571.
3. Dukes CE (1932). The classification of cancer of the rectum. J Pathol Bacteriol 35,323.
4. Astler VB and Coller FA (1954). The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139, 846-852.
5. Ouyang DL, Chen JJ, Getzenberg RH, and Schoen RE (2005). Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 100, 1393-1403.
6. Burch JA, Soares-Weiser K, St John DJ, Duffy S, Smith S, Kleijnen J, and Westwood M (2007). Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 14, 132-137.
7. Doria-Rose VP, Newcomb PA, and Levin TR (2005). Incomplete screening flexible sigmoidoscopy associated with female sex, age, and increased risk of colorectal cancer. Gut 54, 1273-1278.
8. Huang EH, Carter JJ, Whelan RL, Liu YH, Rosenberg JO, Rotterdam H, Schmidt AM, Stern DM, and Forde KA (2002). Colonoscopy in mice. Surg Endosc 16, 22-24.
9. Becker C, Fantini MC, and Neurath MF (2006). High resolution colonoscopy in live mice. Nat Protoc 1, 2900-2904.
10. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, and Wang XF (1999). Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol Cell Biol 19, 2495-2504.
11. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, and Iritani BM (2006). Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 66, 828-838.
12. Fox JG, Yan L, Shames B, Campbell J, Murphy JC, and Li X (1996). Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect Immun 64, 3673-3681.
13. Myles MH, Livingston RS, Livingston BA, Criley JM, and Franklin CL (2003). Analysis of gene expression in ceca of Helicobacter hepaticus-infected A/JCr mice before and after development of typhlitis. Infect Immun 71, 3885-3893.
14. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, and Markowitz S (1998). Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58, 3101-3104.
15. Markowitz SD and Bertagnolli MM (2009). Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361, 2449-2460.
16. Livingston RS, Riley LK, Steffen EK, Besch-Williford CL, Hook RR Jr, and Franklin CL (1997). Serodiagnosis of Helicobacter hepaticus infection in mice by an enzyme-linked immunosorbent assay. J Clin Microbiol 35, 1236-1238.
17. Riley LK, Franklin CL, Hook RR Jr, and Besch-Williford C (1996). Identification of murine helicobacters by PCR and restriction enzyme analyses. J Clin Microbiol 34,942-946.
18. O'Garra A, Chang R, Go N, Hastings R, Haughton G, and Howard M (1992). Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 22, 711-717.
19. Kruessel JS, Huang HY, Wen Y, Kloodt AR, Bielfeld P, and Polan ML (1997). Different pattern of interleukin-1 β- (IL-1 β), interleukin-1 receptor antagonist- (IL-1ra) and interleukin-1 receptor type I- (IL-1R tI) mRNA-expression in single preimplantation mouse embryos at various developmental stages. J Reprod Immunol 34, 103-120.
20. Huang DR, Wang J, Kivisakk P, Rollins BJ, and Ransohoff RM (2001). Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 193, 713-726.
21. Myles MH, Dieckgraefe BK, Criley JM, and Franklin CL (2007). Characterization of cecal gene expression in a differentially susceptible mouse model of bacterial- induced inflammatory bowel disease. Inflamm Bowel Dis 13, 822-836.
22. Team RDC (2010). R: A Language and Environment for Statistical Computing.
23. Brasil P (2010). DiagnosisMed: Diagnostic Test Accuracy Evaluation for Medical Professionals.
24. Vinterbo SA (2007). gcl: Compute a Fuzzy Rules or Tree Classifier from Data.
25. Zhu Y, Richardson JA, Parada LF, and Graff JM (1998). Smad3 mutant mice develop metastatic colorectal cancer. Cell 94, 703-714.
26. DeLong ER, DeLong DM, and Clarke-Pearson DL (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845.
27. Hanley JA and McNeil BJ (1983). A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148, 839-843.
28. Symonds DA and Vickery AL (1976). Mucinous carcinoma of the colon and rectum. Cancer 37, 1891-1900.
29. Kakar S, Aksoy S, Burgart LJ, and Smyrk TC (2004). Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 17, 696-700.
30. Leopoldo S, Lorena B, Cinzia A, Gabriella DC, Angela Luciana B, Renato C, Antonio M, Carlo S, Cristina P, Stefano C, et al. (2008). Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 15, 1429-1439.
31. Halvorsen TB and Seim E (1988). Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol 41, 1068-1072.
32. Wyatt MG, Houghton PW, Mortensen NJ, and Williamson RC (1987). The malignant potential of colorectal Crohn's disease. Ann R Coll Surg Engl 69, 196-198.
33. Levin KE and Dozois RR (1991). Epidemiology of large bowel cancer. World J Surg 15, 562-567.
34. Rubio CA and Befrits R (1997). Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study. Dis Colon Rectum 40, 1072-1078.
35. Winkler R, Wittmer A, and Heusermann U (2002). Cancer and Crohn's disease. Z Gastroenterol 40, 569-576.
36. Hamilton SR (1985). Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 89, 398-407.
37. Itzkowitz SH and Yio X (2004). Inflammation and cancer: IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287, G7-G17.
38. Choi PM and Zelig MP (1994). Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35, 950-954.
39. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, and Taylor WF (1973). Crohn's disease and cancer. N Engl J Med 289, 1099-1103.
40. Ky A, Sohn N, Weinstein MA, and Korelitz BI (1998). Carcinoma arising in anorectal fistulas of Crohn's disease. Dis Colon Rectum 41, 992-996.
41. Moore-Maxwell CA and Robboy SJ (2004). Mucinous adenocarcinoma arising in rectovaginal fistulas associated with Crohn's disease. Gynecol Oncol 93, 266-268.
42. Ying LT, Hurlbut DJ, Depew WT, Boag AH, and Taguchi K (1998). Primary adenocarcinoma in an enterocutaneous fistula associated with Crohn's disease. Can J Gastroenterol 12, 265-269.
43. Kudo K, Funayama Y, Fukushima K, Shibata C, Takahashi K, Ogawa H, Ueno T, Haneda S, Watanabe K, Koyama A, et al. (2007). Carcinoma arising from ileorectal fistula in a patient with Crohn's disease. Nippon Shokakibyo Gakkai Zasshi 104,1492-1497.
44. Smith R, Hicks D, Tomljanovich PI, Lele SB, Rajput A, and Dunn KB (2008). Adenocarcinoma arising from chronic perianal Crohn's disease: case report and review of the literature. Am Surg 74, 59-61.
45. Kuehle CA, Langhorst J, Ladd SC, Zoepf T, Nuefer M, Grabellus F, Barkhausen J, Gerken G, and Lauenstein TC (2007). Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population. Gut 56,1079-1085.
46. Alexander RJ and Raicht RF (1998). Purification of total RNA from human stool samples. Dig Dis Sci 43, 2652-2658.
47. Hasegawa Y, Takeda S, Ichii S, Koizumi K, Maruyama M, Fujii A, Ohta H, Nakajima T, Okuda M, Baba S, et al. (1995). Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele- specific amplification (MASA). Oncogene 10, 1441-1445.
48. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, and Kritchevsky SB (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14, 2413-2418.
49. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A, and Allavena P (2009). Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 460, 105-121.
50. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, et al. (2007). High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67, 4725-4731.
51. Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, Peck D, and Darzi A (2007). Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24, 121-130.
52. Lewis CE and Pollard JW (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66, 605-612.
53. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, and Hopt UT (2005). Chemokines in human colorectal carcinoma. Anticancer Res 25, 3581-3584.
54. Dinarello CA (1996). Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147.
55. Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, Hostetter J, and Wannemuehler MJ (2007). Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/ HeN mice. Gut 56, 934-940.
56. Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S, Bartfai T, and Mantovani A (2002). Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 168, 3557-3562.
57. Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD, Fan F, Takeda A, Akagi M, et al. (2003). Cyclooxygenase-2 is up-regulated by interleukin-1β in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63, 3632-3636.
58. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, and Hla T (1995). Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55, 3785-3789.
59. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, and Gooderham NJ (2003). Expression of cyclooxygenase-2 parallels expression of interleukin-1β, interleukin-6 and NF-κB in human colorectal cancer. Carcino- genesis 24, 665-671.
60. Tsujii M and DuBois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501.
61. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and DuBois RN (1998). Cyclo- oxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716.
62. Kanaoka S, Yoshida K, Miura N, Sugimura H, and Kajimura M (2004). Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127, 422-427.
63. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M, and Hishida A (2009). Fecal cyclooxygenase 2 plus matrix metallo- proteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 18, 1888-1893.
64. Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, Fischer JR, Lorenzoni M, Givel JC, and Odartchenko N (1992). Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor β1. Eur J Cancer 28A, 1894-1899.
65. Enss ML, Cornberg M, Wagner S, Gebert A, Henrichs M, Eisenblatter R, Beil W, Kownatzki R, and Hedrich HJ (2000). Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 49, 162-169.
66. Jarry A, Vallette G, Branka JE, and Laboisse C (1996). Direct secretory effect of interleukin-1 via type I receptors in human colonic mucous epithelial cells (HT29- C1.16E). Gut 38, 240-242.
67. Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA, and Cuber JC (1998). Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275, G1073-G1084.
68. Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, and Kato I (2008). Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis ofbiomarkersofgastrointestinalcancer.CancerEpidemiolBiomarkersPrev 17,455-458.
69. Van Lieshout EM, Van Doesburg W, and Van der Meer R (2004). Real-time PCR of host DNA in feces to study differential exfoliation of colonocytes between rats and humans. Scand J Gastroenterol 39, 852-857.
70. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, and DuBois RN (2000). Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 118, 337-345.
71. Sohn KJ, Shah SA, Reid S, Choi M, Carrier J, Comiskey M, Terhorst C, and Kim YI (2001). Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2- and β(2)-microglobulin-deficient mouse. Cancer Res 61, 6912-6917.
72. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, and Birnbaumer L (1995). Ulcerative colitis and adenocarcinoma of the colon in Gαi2-deficient mice. Nat Genet 10, 143-150.